volume 2, issue 8, PS413 2007
DOI: 10.1097/01.jto.0000283298.56701.a0
View full text
|
|
Share

Abstract: Background: Over-expression of Akt and loss of PTEN are frequent events in non-small cell lung cancer (NSCLC). The mammalian target of rapamycin (mTOR) is a protein downstream to Akt in the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. CCI-779 (temsirolimus), an ester of sirolimus, is an inhibitor of mTOR with growth inhibitory activity in a variety of tumor cells. In an effort to evaluate the single agent activity of CCI-779 in previously untreated NSCLC, the NCCTG undertook a front-line "window…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
8
0
1

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals